Slingshot Insights | Nvs Overview

NVS Overview

Upcoming Projects (NVS)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (NVS)

A Second Opinion: Looking at the recent Phase 3 results on Scholar Rock's apitegromab for Spinal Muscular Atrophy
Tickers: SRRK, RHHBF, BHVN, BIIB, NVS
Executed On: Oct 22, 2024 at 06:00 PM EDT
Quarterly Survey: PSMA PET Imaging Agents Trends & Preferences October 2024
Tickers: LNTH, NVS, Telix, Blue Earth Diagnostics
Executed On: Oct 18, 2024 at 02:53 PM EDT
Quarterly Survey: mCRPC and Pluvico Lutetium-177 PSMA Therapy October 2024
Ticker: NVS
Executed On: Oct 18, 2024 at 02:00 PM EDT
Discussing commercial and investigational agents in development for IgAN
Tickers: VRTX, NVS
Executed On: Oct 16, 2024 at 08:00 AM EDT
Discussing the 52 week results of the Barzolvolimab Phase 2 study in CSU (Chronic Spontaneous Urticaria) at EADV 2024
Tickers: CLDX, JSPR, REGN, NVS
Executed On: Oct 09, 2024 at 12:00 PM EDT
Discussing BTK inhibitors in autoimmune indications
Tickers: NVS, BMY, GILD, SNY
Executed On: Oct 01, 2024 at 01:30 PM EDT
Quarterly Survey: PSMA PET Imaging Agents Trends & Preferences July 2024
Tickers: LNTH, NVS, Telix, Blue Earth Diagnostics
Executed On: Jul 26, 2024 at 12:26 PM EDT
Discussing the use of PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) to treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies.
Ticker: NVS
Executed On: Jul 26, 2024 at 11:00 AM EDT
Quarterly Survey: mCRPC and Pluvico Lutetium-177 PSMA Therapy July 2024
Ticker: NVS
Executed On: Jul 23, 2024 at 01:31 PM EDT
Quarterly Survey: PSMA PET Imaging Agents Trends & Preferences April 2024
Tickers: LNTH, NVS, Telix, Blue Earth Diagnostics
Executed On: Apr 24, 2024 at 04:49 PM EDT
Quarterly Survey: mCRPC and Pluvico Lutetium-177 PSMA Therapy April 2024
Ticker: NVS
Executed On: Apr 18, 2024 at 04:45 PM EDT
Discussing iptacopan and the results of the APPEAR-C3G study in patients with C3 Glomerulopathy
Ticker: NVS
Executed On: Mar 05, 2024 at 04:00 PM EST
Discussing the appropriate use and future of Pluvicto Radionuclide Therapy amidst the developing treatment landscape for genitourinary cancers.
Tickers: NVS, FUSN, RYZB, PNT
Executed On: Feb 02, 2024 at 08:00 AM EST
Quarterly Survey: PSMA PET Imaging Agents Trends and Preferences January 2024
Tickers: LNTH, NVS, Telix, Blue Earth Diagnostics
Executed On: Jan 23, 2024 at 04:08 PM EST
Quarterly Survey: mCRPC and Pluvico Lutetium-177 PSMA Therapy January 2024
Ticker: NVS
Executed On: Jan 23, 2024 at 03:24 PM EST
A look at theranostic imaging and Targeted Alpha Therapy.
Tickers: LNTH, NVS, RYZB, PNT
Executed On: Jan 12, 2024 at 02:00 PM EST
Delving into the recent phase 3 data from the ALIGN clinical trial of Novartis' atrasentan in patients with IgA Nephropathy.
Tickers: NVS, TVTX, CALT, KDNY
Executed On: Nov 17, 2023 at 09:00 AM EST
Digging into the Phase 3 trial of Novartis' Pluvicto (Lu-PSMA-617) in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore) as presented at ESMO 2023
Ticker: NVS
Executed On: Nov 14, 2023 at 10:00 AM EST
Key Takeaways from ESMO 2023: A conversation with an oncologist attending the conference
Tickers: SGEN, MRK, NVS, MRTX, JNJ
Executed On: Nov 07, 2023 at 01:00 PM EST
Quarterly Survey: PSMA PET Imaging Agents Trends and Preferences - October 2023
Tickers: LNTH, NVS, Telix, Blue Earth Diagnostics
Executed On: Nov 02, 2023 at 12:12 PM EDT
Quarterly Survey: mCRPC and Pluvicto Lutetium-177 PSMA Therapy October 2023
Ticker: NVS
Executed On: Nov 02, 2023 at 11:39 AM EDT
Getting a prescriber's perspective comparing Briumvi, Ocrevus and Kesimpta in treating multiple sclerosis
Tickers: TGTX, RHHBY, NVS
Executed On: Oct 03, 2023 at 06:00 PM EDT
Quarterly Survey: mCRPC and Pluvicto Lutetium-177 PSMA Therapy July 2023
Ticker: NVS
Executed On: Jul 25, 2023 at 05:53 PM EDT
A Third Opinion: Digging into the IgAN landscape with a focus on Travere's Filspari (sparsentan), Calliditas' Nefecon (Tarpeyo/Kinpeygo), and Chinook's Atrasentan
Tickers: CALT, NVS, TVTX, KDNY
Executed On: Jun 13, 2023 at 04:00 PM EDT
A Second View: Discussing the potential of CD20 as class in treating Multiple Sclerosis with a focus on BRIUMVI, Kesimpta, and Ocrevus
Tickers: TGTX, NVS, RHHBY
Executed On: May 12, 2023 at 05:00 PM EDT
Discussing the potential of CD20 as class in treating Multiple Sclerosis with a focus on BRIUMVI, Kesimpta, and Ocrevus
Tickers: TGTX, NVS, RHHBY
Executed On: May 11, 2023 at 02:30 PM EDT
Quarterly Survey: mCRPC and Pluvicto Lutetium-177 PSMA Therapy April 2023
Ticker: NVS
Executed On: Apr 10, 2023 at 05:43 PM EDT
Discussing the potential of Novartis’ Tafinlar (dabrafenib) and Mekinist (trametinib) combo for BRAF V600E mutated low-grade glioma with a pediatric neuro-oncologist.
Ticker: NVS
Executed On: Mar 27, 2023 at 10:00 AM EDT
Quarterly Survey: Lutetium-177 PSMA Therapy for Prostate Cancer and Notartis' Pluvicto February 2023
Ticker: NVS
Executed On: Feb 14, 2023 at 03:33 PM EST
2 Week Delay: A survey on the PSMA-PET Imaging Agents with a focus on Pluvicto (Novartis Lu-PSMA-617) and PNT-2002 (Lu-PSMA-I&T)
Tickers: NVS, LNTH, PNT
Executed On: Nov 10, 2022 at 05:19 PM EST
A Second Look: Discussing Point Bio's 177Lu-PNT2002 in mCRPC after recent data presented at ESMO 2022
Tickers: PNT, NVS
Executed On: Sep 13, 2022 at 01:00 PM EDT
Discussing the phase 3 SPLASH study (177Lu-PNT2002) from Point Biopharma, and how it may compare to Pluvicto in mCRPC
Tickers: PNT, NVS
Executed On: Aug 25, 2022 at 03:00 PM EDT
Discussion of current NHL CAR-T and outlook for allogeneic therapies in DLBCL
Tickers: BMY, GILD, NVS, CRSP, ALLO, ACET
Executed On: May 03, 2022 at 01:00 PM EDT
Discussing Low-Grade Serous Ovarian Carcinoma (LGSOC) with a specific focus on VS-6766 and trametinib
Tickers: VSTM, NVS
Executed On: Apr 08, 2022 at 11:00 AM EDT
A Conversation on the Chronic Urticaria Landscape
Tickers: CLDX, NVS, RHHBF
Executed On: Jan 04, 2022 at 12:00 PM EST

Expired Projects (NVS)

Quarterly Survey: PSMA PET Imaging Agents Trends and Preferences April 2024
Tickers: LNTH, NVS, Telix, Blue Earth Diagnostics
Execute By: Apr 25, 2024
A Look at Novartis' Cosentyx in treating Hidradenitis Suppurativa and how it can compete with Humira
Tickers: NVS, ABBV, ANAB
Execute By: Aug 08, 2022
SURVEY: Understanding the potential impact of Risdiplam on Spinraza in SMA
Tickers: RHHBY, BIIB, NVS
Execute By: Mar 26, 2021
After its recent IPO we look at Crinetics’ lead pipeline candidate, CRN00808, in treating Acromegaly
Tickers: CRNX, NVS, IPN.PA
Execute By: Nov 07, 2018
Investigating Loxo’s larotrectinib in treating TRK cancers with upcoming data in Q4
Tickers: LOXO, EXEL, RXDX, NVS
Execute By: Dec 12, 2017
A Second Opinion: Preparing for Eptinezumab's data in Chronic Migraine after study changes and additional data from Erenumab
Tickers: ALDR, AMGN, TEVA, NVS
Execute By: May 17, 2017
Evaluating the Chances of Approval and Market Potential of Ariad's Brigatinib in ALK-Positive Non-Small Cell Lung Cancer Before PDUFA of April 29th
Tickers: ARIA, TKPYY, PFE, NVS, RHHBY, Genentech
Execute By: Apr 28, 2017
A third opinion: Does Squalamine stand a good chance of success in the current Phase 3 Wet AMD trial?
Tickers: OHRP, REGN, NVS, Ophthotech
Execute By: Jun 03, 2016
Evaluating the Multiple Sclerosis Market After AbbVie (ABBV) and Biogen (BIIB) Receive CHMP Support for EU Approval of Zinbryta
Tickers: ABBV, BIIB, TEVA, NVS, SNY, MedDay Pharmaceuticals, RHHBY
Execute By: May 23, 2016
Evaluating the Market Potential of Hua Medicine's HMS5552 in Type II Diabetes Ahead of Mid-Year Phase II Readout. Does the drug have potential to derail the success of major players in the space?
Tickers: HUA MEDICINE, ABT, AZN, NVS, NVO, MRK, SNY, GSK, Lupin Pharmaceuticals, RHHBY
Execute By: May 11, 2016

Upcoming & Overdue Catalysts (NVS)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (NVS)

Novartis (NVS) stops development of fevipiprant LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
Tickers: NVS, GOSS
Occurred on: Dec 16, 2019
Novartis (NVS) to submit biosimilar Pegfilgrastim for bone marrow stimulation to FDA in early 2019
Ticker: NVS
Occurred on: Apr 03, 2019
Two-year data for Novartis' (NVS) brolucizumab versus aflibercept in reducing retinal fluid in patients with nAMD
Ticker: NVS
Occurred on: Oct 27, 2018
Amgen (AMGN) set for FDA action date for migraine treatment Erenumab on May 17th, 2018
Ticker: NVS
Occurred on: May 18, 2018
Novartis (NVS) to submit CL-019 for Diffuse large B-cell lymphoma (DLBCL) in the U.S. in Q4 of 2017
Ticker: NVS
Occurred on: May 01, 2018
Novartis (NVS) presented new Cosentyx (secukinumab) data from the prospective Phase III SCALP study
Ticker: NVS
Occurred on: Feb 16, 2018
Novartis (NVS) to submit biosimilar Adalimumab to FDA for arthritis in second half of 2017
Ticker: NVS
Occurred on: Jan 16, 2018
Novartis (NVS) to present full Phase 3 study data on RTH-258 treating Neurovascular Age-Related Macular Degeneration (AMD) at the American Academy of Ophthalmology Meeting on November 10th, 2017
Ticker: NVS
Occurred on: Nov 10, 2017
Following approval recommendation from FDA Advisory Committee for CTL-019 in pediatric Acute lymphoblastic leukemia (ALL), Novartis to submit drug to Europe for approval by end of 2017
Ticker: NVS
Occurred on: Nov 06, 2017
Novartis (NVS) to submit biosimilar Pegfilgrastim for bone marrow stimulation to EU in second half of 2017
Ticker: NVS
Occurred on: Oct 27, 2017
Novartis (NVS) receives first ever FDA approval for a CAR-T cell therapy, Kymriah (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
Ticker: NVS
Occurred on: Aug 30, 2017
Novartis (NVS) CANTOS to share Phase 3 data on ACZ-885 targeting inflammation to reduce cardiovascular risk on August 27th. 2017
Ticker: NVS
Occurred on: Aug 27, 2017
Topline results released for Novartis' (NVS) Phase III study of ACZ885 (canakinumab) in reducing cardiovascular risk in people who survived a heart attack
Ticker: NVS
Occurred on: Jun 22, 2017
Data from Novartis' (NVS) RTH258 (brolucizumab) Phase 3 study in nAMD patients released
Ticker: NVS
Occurred on: Jun 20, 2017
Novartis' (NVS) FDA Priority Review Expected By May 14th for Midostaurin (PKC412) in Treatment of Acute Myeloid Leukemia (AML) in Newly-Diagnosed Adults with an FMS-Like Tyrosine Kinase-3 (FLT3) Mutation
Ticker: NVS
Occurred on: Apr 28, 2017
FDA Grants Breakthrough Therapy Status to Novartis' (NVS) CTL019 in Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL)
Ticker: NVS
Occurred on: Apr 18, 2017
FDA approves Novartis' (NVS) BLA for CAR-T drug candidate CTL019—treating pediatrics, young adults with refractory B-cell acute lymphoblastic leukemia—for Priority Review
Ticker: NVS
Occurred on: Mar 29, 2017
Novartis (NVS) agrees to license to PureTech Health two mTORC1 inhibitors in studying age-related focuses. New ew subsidiary called resTORbio will head developments of these candidates.
Ticker: NVS
Occurred on: Mar 24, 2017
FDA Decision Expected in Early April for Novartis' (NVS) Marketing Application for Robociclib in HR+/HER2- Advanced Breast Cancer
Ticker: NVS
Occurred on: Mar 13, 2017
FDA Accepts Novartis' (NVS) Supplemental New Drug Application (sNDA) Under Priority Review for Zykadia (Ceritinib) in First-Line Treatment of Metastatic ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Ticker: NVS
Occurred on: Feb 23, 2017
Novartis (NVS) Announces Plans for Phase 2 Trial Assessing MorphoSys Ag's (MPSYF) Bimagrumab in Obese Patients with Type 2 Diabetes
Tickers: NVS, MPSYF
Occurred on: Jan 12, 2017
Final Decision Expected from European Commission in ~60 Days on Novarits' (NVS) Arzerra in Adult Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)
Ticker: NVS
Occurred on: Dec 12, 2016
Novartis (NVS) Presents Phase 3 MONALEESA-2 Data Evaluating LEE011 + Femara in Patients with Hormone-Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer
Ticker: NVS
Occurred on: Dec 09, 2016
European Commission Adopts Positive Opinion Recommending Novartis' (NVS) Arzerra in Adults with Relapsed Chronic Lymphocytic Leukemia (CLL)
Ticker: NVS
Occurred on: Nov 11, 2016
Novartis' (NVS) Gets Priority Review for Ribociclib Marketing Application in First-Line Treatment of HR+/HER2- Advanced Breast Cancer
Ticker: NVS
Occurred on: Nov 01, 2016
Novartis (NVS) late-breaking data show Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patients
Ticker: NVS
Occurred on: Oct 01, 2016
Novartis (NVS) Announces FDA Approval for Expanded Use of Illaris in Periodic Fever Syndrome Conditions
Ticker: NVS
Occurred on: Sep 23, 2016
Novartis (NVS) Announces Top-Line Results from Phase III EXPAND Trial Evaluating BAF312 in Secondary Progressive Multiple Sclerosis
Ticker: NVS
Occurred on: Sep 17, 2016
Pfizer (PFE) Announces Phase 3 REFLECTIONS B537-02 Data Evaluating Remicade Biosimilar in Rheumatoid Arthritis
Tickers: PFE, NVS
Occurred on: Sep 16, 2016
AirFluSal Forspiro showed superiority at 12 months over Seretide Diskus in persistence to treatment
Ticker: NVS
Occurred on: Aug 31, 2016
Genmab Announces FDA Approval of Arzerra (ofatumumab) in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL
Tickers: NVS, GEN.F
Occurred on: Aug 31, 2016
FDA approves Sandoz Erelzi to treat multiple inflammatory diseases
Ticker: NVS
Occurred on: Aug 30, 2016
Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS
Ticker: NVS
Occurred on: Aug 25, 2016
Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer
Ticker: NVS
Occurred on: Aug 03, 2016
FDA Lifts Clinical Hold On CGF166
Tickers: NVS, GNVC
Occurred on: Jul 25, 2016
Ad Comm review July 13 for Novartis Enbrel biosimilar GP2015
Tickers: NVS, AMGN
Occurred on: Jul 12, 2016
Novartis pivotal data for Tafinlar + Mekinist demonstrated a 63 percent overall response rate in treating rare form of lung cancer
Ticker: NVS
Occurred on: Jun 06, 2016
Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna
Ticker: NVS
Occurred on: Jun 04, 2016
Novartis drug Afinitor receives EU approval to treat certain types of advanced gastrointestinal (GI) and lung neuroendocrine tumors (NET)
Ticker: NVS
Occurred on: Jun 02, 2016
Complete Remission Rate of 90%: China-based CAR-T Cell Therapy Achieves Breakthrough Clinical Trial Results
Tickers: INNOVATIVE CELLULAR THERAPEUTICS, NVS, JUNO, KITE
Occurred on: May 06, 2016
Novartis' (NVS) PKC412 for Newly-Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) Designated Breakthrough Therapy by FDA
Ticker: NVS
Occurred on: Feb 19, 2016
Genmab/Novartis' Arzerra (Ofatumumab) as Maintenance Therapy for Relapsed chronic lymphocytic leukemia PDUFA target date set to January 21, 2016
Tickers: NVS, OMX: GEN
Occurred on: Jan 19, 2016
FDA approves Cosentyx in treating patients with ankylosing spondylitis and psoriatic arthritis in the US
Ticker: NVS
Occurred on: Jan 15, 2016
Largest Breast Cancer Study of its Kind Suggests Several New Potential Drug Targets and Combinations; results will be seized on by labs worldwide to identify new drug candidates and pinpoint mechanisms by which cancer cells resist treatment
Tickers: NVS, RHHBY
Occurred on: Jan 14, 2016
Results of the MEASURE 1 and MEASURE 2 Phase III studies for Novartis' Cosentyx (secukinumab) in ankylosing spondylitis (AS) were published
Ticker: NVS
Occurred on: Dec 23, 2015
European Medicines Agency Accepts Bristol-Myers Squibb's (BMY) Type II Variation Application Seeking Expanded Approval for the Treatment of Adults With Advanced Renal Cell Carcinoma
Tickers: BMY, NVS
Occurred on: Nov 05, 2015
Novartis' (NVS) Dual Combination Bronchodilator Inhalation Powder for Treatment of Airflow Obstruction in Patients with Chronic Pulmonary Disease Approved by FDA
Ticker: NVS
Occurred on: Oct 29, 2015

Strategic Initiatives (NVS)

Novartis(NVS) to acquire The Medicines Company(MDCO) for USD 9.7 bn, adding inclisiran, investigational cholesterol-lowering therapy
Tickers: NVS, ARWR, MDCO
Announcement Date: Nov 24, 2019
Takeda Pharmaceutical Co(TAK) to sell eye drug Xiidra to Novartis AG(NVS)
Tickers: NVS, TAK
Announcement Date: May 08, 2019
Allergan (AGN) and Novartis (NVS) Announce Collaboration for Phase 2b Trial Evaluating AGN's Cenicriviroc with NVS' Farnesoid X Receptor (FXR) in Non-Alcoholic Steatohepatitis (NASH)
Tickers: NVS, AGN
Announcement Date: Apr 18, 2017
Novartis (NVS) Out-Licenses Two mTORC1 Inhibitors to PureTech (PTCHF)
Tickers: NVS, PTCHF
Announcement Date: Mar 24, 2017
Novartis (NVS) Out-Licenses U.S Rights to Three Treatments for Chronic Obstructive Pulmonary Disease (COPD) to Sunovion Pharmaceuticals
Tickers: NVS, Sunovion Pharmaceuticals
Announcement Date: Dec 21, 2016
Novartis (NVS) Agrees to Exclusive Worldwide License Agreement for Contaus Pharma's (CNAT) Orally Active Pan-Caspase Inhibitor Emricasan
Tickers: NVS, CNAT
Announcement Date: Dec 19, 2016
Novartis (NVS) Acquires Selexys for $665MM to Expand Portfolio for Blood Disorders
Tickers: NVS, Selexys Pharmaceuticals
Announcement Date: Nov 21, 2016
Cerulean (CERU) Announces Collaboration Agreement with Novartis (NVS) to Develop Nanoparticle-Drug Conjugate (NDC) Product Candidates
Tickers: CERU, NVS
Announcement Date: Oct 19, 2016
Novartis disbands its pioneering cell and gene therapy unit
Tickers: NVS, JUNO, KITE
Announcement Date: Aug 31, 2016
Qualcomm and Novartis will collaborate on a smart inhaler for patients with chronic obstructive pulmonary disease
Tickers: NVS, QCOM
Announcement Date: Jan 05, 2016